Keyphrases
Trastuzumab
100%
Anticancer Immune Response
100%
Natural Killer Cells
100%
Mismatched Related Donor
100%
Anti-breast Cancer
100%
KIR HLA Ligands
100%
Breast Cancer
15%
Tumor Microenvironment
15%
Patient-derived
15%
Breast Cancer Cells
15%
Tumor
10%
Hypoxia
10%
Tumor Cells
10%
Cell Response
10%
KIR Ligand
10%
SKBR3
10%
Suppressive Factor
10%
Treatment Options
5%
Clinically Significant
5%
Combination Therapy
5%
Cytotoxicity
5%
Immune Response
5%
Antitumor Immune Response
5%
Normoxic Conditions
5%
Hypoxic Condition
5%
Patient Tumor
5%
Antitumor Efficacy
5%
Natural Killer
5%
Cell-based
5%
Interleukin-2
5%
Cell-mediated
5%
Strategies to Overcome
5%
HER2 Overexpression
5%
Antibody-dependent Cellular Cytotoxicity
5%
CD107a
5%
Tumor Targeting
5%
Natural Killer Cell Activity
5%
MCF-7
5%
Alloreactive
5%
Donor-derived
5%
4T1 Breast Cancer
5%
Cell Inhibition
5%
Cell Functionality
5%
Natural Killer Cell Degranulation
5%
SKBR3 Cells
5%
Targeting Antibodies
5%
Cancer Cell Cytotoxicity
5%
Antitumor Potential
5%
Natural Killer Cell Receptors
5%
Inhibitory Ligands
5%
Anti-HER2 Antibody
5%
Cell Suppression
5%
HLA Class I Expression
5%
Cell Donors
5%
Tumor Environment
5%
Cultured Cell Lines
5%
INIS
antibodies
100%
cancer
100%
breasts
100%
ligands
100%
natural killer cells
100%
tumors
43%
patients
17%
toxicity
13%
suppression
8%
hypoxia
8%
mice
8%
tumor cells
8%
therapy
4%
receptors
4%
comparative evaluations
4%
inhibition
4%
cytokines
4%
mimic
4%
environment
4%
immunotherapy
4%
Immunology and Microbiology
Trastuzumab
100%
Natural Killer Cell
100%
Antibody-Dependent Cell-Mediated Cytotoxicity
100%
Immunology
100%
Cancer Cell
14%
Immune Response
9%
Cytotoxicity
9%
Tumor Cell
9%
Natural Killer Cell Response
9%
Cytokine
4%
Cell Line
4%
Cell Culture
4%
Interleukin 2
4%
Degranulation
4%
Cell Activation
4%
Immunotherapy
4%